Adverse drug reactions affecting treatment adherence in first-line treatment of asthma: An observational study

Basit Öğe Kaydı
dc.contributor.authorErdem, Semiha Bahceci
dc.contributor.authorNacaroglu, Hikmet Tekin
dc.contributor.authorCan, Demet
dc.date.accessioned2024-03-09T18:48:43Z
dc.date.available2024-03-09T18:48:43Z
dc.date.issued2023
dc.departmentİzmir Bakırçay Üniversitesien_US
dc.description.abstractBackground: Asthma is the most common chronic lung disease among children. International guidelines recommend inhaled corticosteroids (ICS) as the first-line daily controller therapy for children with asthma and leukotriene receptor antagonists (LTRA) as the second alternative therapy. Adherence to treatment is the most significant component to optimize the benefits of therapy in asthma. Objective: This study aims to investigate the frequency of drug discontinuation due to adverse drug reactions (ADRs) that affect adherence to treatment in children with asthma or asthma and allergic rhinitis using LTRA or ICS as monotherapy. Methods: The subjects aged 4-18 years with asthma or asthma and allergic rhinitis and using montelukast or ICS as monotherapy were included in the study. They were evaluated in terms of ADRs affecting adherence to treatment in the first and third months of treatment. Results: A total of 468 cases, 356 of whom received montelukast monotherapy and 112 of whom received ICS treatment, with a mean age of 9.10 +/- 3.08 (4-17) years, were included in the study. Males constituted 65.6% of the total cases (n = 307). In the first month of follow-up of the cases, it was observed that 4.8% (n = 17) of the patients in the montelukast group could not continue the treatment due to ADR. It was determined that the drug discontinuation rate in the montelukast group in the first month was significantly higher than in the ICS group (P = 0.016), and the risk of drug discontinuation due to ADR in the montelukast group was 1.333 (95% CI, 1.26-1.40) times higher. Conclusions: As a result, it was observed that the drug was discontinued due to ADR at a higher rate in children with asthma who received montelukast monotherapy compared to those who received ICS monotherapy. (c) 2023 Codon Publications. Published by Codon Publications.en_US
dc.identifier.doi10.15586/aei.v51i2.774
dc.identifier.endpage16en_US
dc.identifier.issn0301-0546
dc.identifier.issn1578-1267
dc.identifier.issue2en_US
dc.identifier.pmid36916083en_US
dc.identifier.scopus2-s2.0-85150083838en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage11en_US
dc.identifier.urihttps://doi.org/10.15586/aei.v51i2.774
dc.identifier.urihttps://hdl.handle.net/20.500.14034/1434
dc.identifier.volume51en_US
dc.identifier.wosWOS:001011038000002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCodon Publicationsen_US
dc.relation.ispartofAllergologia Et Immunopathologiaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdherence; Adverse Drug Reaction; Asthma; Hallucination; Inhaled Corticosteroids; Leukotriene Receptor Antagonists; Montelukast; Steroid Phobiaen_US
dc.titleAdverse drug reactions affecting treatment adherence in first-line treatment of asthma: An observational studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
1434.pdf
Boyut:
338.13 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu